Showing 1,321 - 1,340 results of 63,758 for search '(( 50 ((ms decrease) OR (a decrease)) ) OR ( 10 ((mean decrease) OR (nn decrease)) ))', query time: 1.17s Refine Results
  1. 1321
  2. 1322
  3. 1323
  4. 1324

    <i>B-MOBILE</i> - A Smartphone-Based Intervention to Reduce Sedentary Time in Overweight/Obese Individuals: A Within-Subjects Experimental Trial by Dale S. Bond (588506)

    Published 2014
    “…However, few sedentary-reducing interventions exist and none have utilized smartphones to automate behavioral strategies to decrease SED. We tested a smartphone-based intervention to monitor and decrease SED in overweight/obese individuals, and compared 3 approaches to prompting physical activity (PA) breaks and delivering feedback on SED.…”
  5. 1325
  6. 1326

    Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  7. 1327

    Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  8. 1328
  9. 1329
  10. 1330
  11. 1331
  12. 1332
  13. 1333
  14. 1334
  15. 1335

    CPGF NPs decrease the growth kinetics of breast cancer cells. by Kirtee D. Wani (636463)

    Published 2014
    “…<p>(<b>A</b>) The NPs decreased the number of cells in MDAMB231 and MCF7, indicated by cell growth assay. …”
  16. 1336
  17. 1337
  18. 1338

    BpiB09 affects the QS-dependent pyocyanin production, <i>C. elegans</i> paralysis in PAO1 and decreases AHL response in <i>A. tumefaciens</i> AHL reporter strain. by Patrick Bijtenhoorn (199146)

    Published 2011
    “…<p><b>A</b>) Decreased pyocyanin production. OD<sub>520</sub> of pyocyanin extracts from culture supernatants of <i>P. aeruginosa</i> carrying pBBR1MCS-5::<i>bpiB09</i> and empty pBBR1MCS-5. …”
  19. 1339
  20. 1340